Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

by B2i | Oct 27, 2022 | Press Releases

JUPITER, Fla., Oct. 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

by B2i | Oct 4, 2022 | Press Releases

JUPITER, Fla., Oct. 04, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Updates Market on Recent Scientific Achievements

by B2i | Sep 13, 2022 | Press Releases

JUPITER, Fla., Sept. 13, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Present at Upcoming Industry and Investor Events in September

by B2i | Sep 8, 2022 | Press Releases

JUPITER, Fla., Sept. 08, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

by B2i | Aug 10, 2022 | Press Releases

Submission of a Clinical Trial Application (CTA) with South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 study to support clinical safety of proteins produced from proprietary C1-cell protein production platform and demonstrate...

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

by B2i | Jul 27, 2022 | Press Releases

JUPITER, Fla., July 27, 2022 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...